MAPT and Lewy body dementia: Considered alongside the growing body of evidence for tau-related cognitive decline and gray matter atrophy in DLB36,52, these findings further implicate tau pathology as a potent disease modifier in DLB and may have potential implications for disease-modifying trials that aim to target not only Lewy body pathology but also AD in individuals with DLB.